Allurar rigakafin zazzabin cizon sauro

Alurar rigakafin zazzabin cizon sauro Ta kasance wata allurar rigakafin cutar zazzabin cizon sauro ne wanda sauro ke kamuwa da shi wanda ya shafi mutane miliyan 249 a duniya a cikin kasashe da yankuna 85 da ke fama da zazzabin cizon sauro kuma ya yi sanadin mutuwar 608,000 a cikin 2022. Alurar riga kafi na farko da aka amince da shi don cutar zazzabin cizon sauro shine RTS,S, wanda aka sani da sunan mai suna Mosquirix.   , an ba da maganin zuwa 1.5yara miliyan da ke zaune a wuraren da zazzabin cizon sauro ya kai matsakaici zuwa sama.  Yana buƙatar aƙalla allurai uku a cikin jarirai ta hanyar shekaru 2, kuma kashi na huɗu yana ƙara kariya har tsawon shekaru 1-2.   Alurar riga kafi yana rage yawan shiga asibiti daga cutar zazzabin cizon sauro da kusan kashi 30%. 

Ana ci gaba da bincike tare da sauran allurar rigakafin zazzabin cizon sauro. Maganin cutar zazzabin cizon sauro mafi inganci shine R21/Matrix-M, tare da ƙimar ingancin 77% da aka nuna a gwaji na farko kuma mafi girman matakan rigakafi fiye da maganin RTS,S. Ita ce rigakafin farko da ta cimma burin Hukumar Lafiya ta Duniya (WHO) na rigakafin cutar zazzabin cizon sauro tare da aƙalla kashi 75% na inganci,   kuma kawai maganin zazzabin cizon sauro na biyu wanda WHO ta ba da shawarar.  A watan Afrilun 2023, Hukumar Abinci da Magunguna ta Ghana ta amince da yin amfani da maganin R21 don amfani da shi ga yara masu shekaru tsakanin watanni biyar zuwa shekaru uku.  Bayan shawarar Ghana, Najeriya ta amince da rigakafin R21 na wucin gadi. 

 Amintattun alluran rigakafi 

 RTS, S 
RTS, S/AS01 (sunan mai suna Mosquirix)  shine maganin zazzabin cizon sauro na farko da aka amince don amfanin jama'a. Yana buƙatar aƙalla allurai uku a cikin jarirai ta hanyar shekaru 2, tare da kashi na huɗu yana ƙara kariya har tsawon shekaru 1-2.  Alurar riga kafi yana rage yawan shiga asibiti daga cutar zazzabin cizon sauro da kusan kashi 30%. 

RTS,S an haɓaka ta PATH Malaria Vaccine Initiative (MVI) da GlaxoSmithKline (GSK) tare da tallafi daga Gidauniyar Bill da Melinda Gates . Alurar rigakafi ce mai sake haɗuwa, wanda ya ƙunshi furotin na Plasmodium falciparum circumsporozoite (CSP) daga matakin pre-erythrocytic. CSP antigen yana haifar da samar da ƙwayoyin rigakafi masu iya hana mamayewar hepatocytes kuma yana haifar da amsawar salula wanda ke ba da damar lalata hanta masu kamuwa da cuta. Alurar rigakafi ta CSP ta gabatar da matsaloli a matakin gwaji saboda rashin isasshen rigakafi . RTS,S yayi ƙoƙari ya guje wa waɗannan ta hanyar haɗa furotin tare da antigen na saman daga cutar hanta B, haifar da ƙarin ƙarfi da rigakafin rigakafi. Lokacin da aka gwada shi a cikin gwaji a matsayin emulsion na man fetur a cikin ruwa kuma tare da ƙarin adjuvants na monophosphoryl A da QS21 (SBAS2), maganin ya ba da kariya ga 7 daga cikin 8 masu aikin sa kai lokacin da aka kalubalanci P. falciparum. 

RTS,S an ƙera shi ta hanyar amfani da kwayoyin halitta daga furotin na waje na P. falciparum malaria parasite da wani yanki na kwayar cutar hanta B tare da wani sinadari don haɓaka amsawar rigakafi. Ana hana kamuwa da cuta ta hanyar haifar da manyan titers na antibody waɗanda ke toshe ƙwayar cuta daga kamuwa da hanta.  A cikin Nuwamba 2012, gwaji na Phase III na RTS,S ya gano cewa yana ba da kariya mai sauƙi daga duka na asibiti da kuma zazzabin cizon sauro a cikin ƙananan jarirai. 

A cikin Oktoban shekarar 2013, sakamakon farko na gwaji na asibiti na kashi III ya nuna cewa RTS,S/AS01 ya rage yawan lokuta a tsakanin yara ƙanana da kusan kashi 50 cikin ɗari kuma tsakanin jarirai da kusan kashi 25 cikin ɗari. Nazarin ya ƙare a cikin shekarar 2014. Tasirin kashi mai kara kuzari yana da inganci, duk da cewa tasirin gabaɗaya yana raguwa da lokaci. Bayan shekaru hudu, raguwa ya kasance kashi 36 cikin dari ga yaran da suka sami allura uku da kuma adadin kuzari. Rashin kashi mai ƙarawa yana rage tasirin cutar zazzabin cizon sauro zuwa wani sakamako mara kyau. An nuna cewa allurar ba ta da tasiri ga jarirai. Allurai uku na alluran rigakafi tare da haɓakawa sun rage haɗarin cututtukan asibiti da kashi 26 cikin ɗari sama da shekaru uku amma ba su ba da wata muhimmiyar kariya daga cutar zazzabin cizon sauro ba. 

A cikin ƙoƙari don saukar da ƙungiyar da ta fi girma kuma ta ba da tabbacin ci gaba da kasancewa ga jama'a, GSK ya nemi lasisin tallace-tallace tare da Hukumar Kula da Magunguna ta Turai (EMA) a cikin Yulin shekarar 2014. GSK ta dauki aikin a matsayin wani shiri na sa-kai, tare da mafi yawan kudaden da aka samu daga gidauniyar Gates, wadda ke taimakawa wajen kawar da zazzabin cizon sauro.

A cikin Yulin shekarar 2015, Mosquirix ya sami kyakkyawar ra'ayi na kimiyya daga Hukumar Kula da Magunguna ta Turai (EMA) game da shawarar da za a yi amfani da maganin alurar riga kafi ga yara masu shekaru 6 makonni zuwa watanni 17 a waje da Tarayyar Turai.  An kaddamar da aikin gwajin rigakafin ne a ranar 23 ga watan Afrilu, shekara ta 2019 a Malawi, a ranar 30 ga Afrilu 2019 a Ghana, da kuma ranar 13 ga watan Satumban shekarar 2019 a Kenya .

A watan Oktoba a shekarar 2021, Hukumar Lafiya ta Duniya ta amince da maganin don "amfani da yawa" ga yara, wanda ya zama rigakafin cutar zazzabin cizon sauro na farko da ya karɓi wannan shawarar.

Kungiyar WHO ce ta cancanta a cikin watan Yulin shekara ta 2022.  A watan Agustan shekarar 2022, UNICEF ta ba da kwangila ga GSK don samar da allurai guda miliyan 18 na rigakafin RTS, S sama da shekaru uku. Fiye da kasashe 30 suna da wuraren da ke da cutar zazzabin cizon sauro inda ake sa ran maganin zai yi samu amfani. 

Ya zuwa watan Afrilu na shekara ta , yara miliyan 1.5 a Ghana, Kenya da Malawi sun karɓi akalla allurar rigakafin guda ɗaya, tare da fiye da allurar rigakawa miliyan 4.5 da aka ba da su ta hanyar shirye-shiryen rigakafin yau da kullun. Kasashe 9 na gaba da za su karɓi allurar rigakafin a cikin shekaru 2 masu zuwa sune Benin, Burkina Faso, Burundi, Kamaru, Jamhuriyar Demokradiyyar Kongo, Laberiya, Nijar, Saliyo, da Uganda.

R21/Matrix-M 
Mafi inganci maganin zazzabin cizon sauro shine R21/Matrix-M, tare da ingancin kashi 77 da aka nuna a gwaji na farko. Ita ce rigakafin farko da ta cimma burin Hukumar Lafiya ta Duniya na maganin zazzabin cizon sauro tare da aƙalla kashi 75 cikin ɗari.  An haɓaka ta ta hanyar haɗin gwiwar da ke tattare da Cibiyar Jenner a Jami'ar Oxford, Cibiyar Nazarin Kiwon Lafiya ta Kenya, Makarantar Kiwon Lafiya ta London da Magungunan Wuta, Novavax, da Cibiyar Serum ta Indiya . An gudanar da gwaje-gwajen ne a Institut de Recherche en Sciences de la Santé da ke Nanoro, Burkina Faso tare da Halidou Tinto a matsayin babban mai bincike.  Alurar riga kafi na R21 yana amfani da sunadaran sunadaran sunadaran (CSP), a mafi girma fiye da na RTS, S. Yana amfani da tsarin haɗin HBsAg iri ɗaya, amma ba ya ƙunshi ƙarin HBsAg.  Ya haɗa da matrix-M adjuvant wanda kuma ake amfani dashi a cikin rigakafin Novavax COVID-19 . 

An ba da rahoton gwajin lokaci na II a cikin Afrilun shekarar 2021, tare da ingancin allurar rigakafi na 77% da matakan rigakafi da yawa fiye da na RTS, S. Harbin ƙarfafawa na R21/Matrix-M wanda aka ba da watanni 12 bayan tsarin kashi uku na farko yana da tasiri mai yawa akan zazzabin cizon sauro, yana ba da kariya mai girma daga cutar cizon sauro na alamar aƙalla shekaru 2.  An bayar da rahoton wani gwaji na kashi na uku tare da yara 4,800 a fadin kasashen Afirka hudu a watan Nuwamban shekarar 2022, wanda ke nuna ingancin alluran rigakafin kashi 74% a kan wani mummunan cutar zazzabin cizon sauro.  Ana tattara ƙarin bayanai daga karatu da yawa.   Ba a buga bayanai daga binciken kashi na III ba bisa ka'ida, amma bayanan da suka gabata daga binciken an raba su da hukumomin gudanarwa. 

Hukumar Kula da Abinci da Magunguna ta Ghana ta amince da amfani da allurar R21 a watan Afrilun shekara ta 2023, don amfani da shi ga yara 'yan tsakanin watanni biyar zuwa shekaru uku. Cibiyar Serum ta Indiya tana shirin samar da allurai tsakanin allurai miliyan 100-200 a kowace shekara, kuma tana gina masana'antar rigakafin a Accra, Ghana .   Bayan shawarar Ghana, Najeriya ta amince da rigakafin R21 na wucin gadi. 

A cikin Oktoban shekarar 2023 WHO ta amince da rigakafin R21 na zazzabin cizon sauro, karshen Disamban shekarar 2023 an saka shi cikin jerin allurar rigakafin da aka rigaya . 

 Karkashin ci gaban wakilai 
Babu wata allurar rigakafi mai inganci don cutar zazzabin cizon sauro, kodayake ana ci gaba da samar da alluran rigakafi da yawa.  Masu neman alluran rigakafi da yawa waɗanda ke yin niyya zuwa matakin-jini na rayuwar parasite ɗin ba su wadatar da kansu ba.  Ana samar da wasu yuwuwar alluran rigakafi da ke niyya da matakin pre-erythrocytic, tare da RTS,S da R-21/Matrix-M zaɓuɓɓukan da aka amince da su zuwa yanzu.   

 Nanoparticle haɓakawa na RTS,S 
In 2015, researchers used a repetitive antigen display technology to engineer a nanoparticle that displayed malaria specific B cell and T cell epitopes. The particle exhibited icosahedral symmetry and carried on its surface up to 60 copies of the RTS,S protein. The researchers claimed that the density of the protein was much higher than the 14% of the GSK vaccine.

 PfSPZ maganin alurar riga kafi 
Alurar riga kafi na PfSPZ wani ɗan takara maganin zazzabin cizon sauro ne wanda Sanaria ya haɓaka ta amfani da sporozoites masu raɗaɗi da radiation don haifar da amsawar rigakafi. Gwaje-gwajen asibiti sun kasance masu ban sha'awa, tare da gwaji a Afirka, Turai, da Amurka suna kare sama da kashi 80% na masu aikin sa kai.  An fuskanci wasu suka game da yuwuwar yiwuwar samar da kayayyaki da yawa a Afirka, tunda dole ne a adana shi cikin ruwa nitrogen .

Hukumar Abinci da Magunguna ta Amurka ta ba da ɗan takarar rigakafin PfSPZ da sauri a cikin Satumba 2016. 

A cikin Afrilun shekarar 2019, an ba da sanarwar gwajin lokaci na III a Bioko, wanda aka shirya farawa a farkon 2020. 

 Sauran abubuwan ci gaba 

 SPf66 allurar rigakafin peptide ce ta roba wanda ƙungiyar Manuel Elkin Patarroyo ta haɓaka a Colombia, kuma an gwada shi sosai a wuraren da ke fama da cutar a cikin shekarun 1990s. Gwaje-gwaje na asibiti sun nuna rashin isasshen inganci, tare da inganci 28% a Kudancin Amurka kuma ƙarancin inganci ko babu inganci a Afirka.  Wannan maganin ba shi da wani tasiri na kariya a cikin mafi girman gwajin da aka sarrafa bazuwar placebo a Kudancin Gabashin Asiya kuma an yi watsi da shi. 
 CSP (Circum-Sporozoite Protein) wani maganin rigakafi ne da aka samar wanda da farko ya bayyana yana da alƙawarin isa ga gwaji. Hakanan yana dogara ne akan furotin na circumsporozoite, amma kuma yana da recombinant (Asn-Ala-Pro15Asn-Val-Asp-Pro) 2-Leu-Arg ( R32LR ) sunadaran da aka haɗa tare da ingantaccen sinadarin Pseudomonas aeruginosa (A9). Duk da haka, a farkon matakin, an nuna cikakken rashin kariya ga waɗanda aka yi wa allurar. Ƙungiyar binciken da aka yi amfani da ita a Kenya tana da kashi 82% na cutar parasitaemia yayin da ƙungiyar kulawa kawai ke da kashi 89% kawai. Maganin da aka yi niyya don haifar da ƙarar amsawar T-lymphocyte a cikin waɗanda aka fallasa; wannan kuma ba a kiyaye ba. 
 Rikicin NYVAC-Pf7 da yawa ya yi ƙoƙarin yin amfani da fasaha daban-daban, wanda ya haɗa da ƙwayoyin antigenic P. falciparum guda bakwai. Waɗannan sun fito ne daga matakai daban-daban yayin zagayowar rayuwa. CSP da sporozoite surface protein 2 (wanda ake kira PfSSP2 ) an samo su daga lokacin sporozoite. Hanta matakin antigen 1 (LSA1), uku daga matakin erythrocytic (protein surface merozoite 1, serine repeat antigen, da AMA-1), da kuma antigen mataki guda daya (25-kDa Pfs25) an haɗa su. An fara bincikar wannan ta hanyar amfani da birai na rhesus kuma an samar da sakamako masu ƙarfafawa: 4 daga cikin 7 antigens sun samar da takamaiman martanin rigakafi (CSP, PfSSP2, MSP1 da PFs25). Gwaji daga baya a cikin mutane, duk da nuna martanin rigakafi na salula a cikin sama da kashi 90% na batutuwan, suna da mummunan martanin rigakafin mutum. Duk da wannan biyo bayan gudanar da maganin, wasu 'yan takarar sun sami cikakkiyar kariya lokacin da aka kalubalanci P. falciparum . Wannan sakamakon yana da garantin gwaji mai gudana. 
 A cikin shekara ta 1995 gwajin filin da ya shafi [NANP] 19-5.1 ya tabbatar da nasara sosai. Daga cikin yara 194 da aka yi wa alurar riga kafi, babu wanda ya kamu da cutar zazzabin cizon sauro a cikin makonni 12 da suka biyo baya, kuma 8 ne kawai suka kasa samun mafi girman matakan rigakafin cutar. Alurar riga kafi ya ƙunshi furotin fitarwa na schizont (5.1) da maimaita 19 na furotin saman sporozoite [NANP]. Iyaka na fasaha ya wanzu saboda yana ƙunshe da 20% peptide kawai kuma yana da ƙananan matakan rigakafi. Hakanan baya ƙunsar kowane epitopes T-cell immunodominant . 
 Ginin sinadarai da ke fuskantar gwaji don maganin tarin fuka da ciwon daji-mai hana JmJc ML324 da dan takarar asibiti na antitubercular SQ109-watakila sabon layin magunguna ne don magance zazzabin cizon sauro da kuma kashe kwayar cutar a matakinsa na kamuwa da cuta. Ana buƙatar ƙarin gwaje-gwaje har yanzu kafin a amince da mahadi a matsayin ingantaccen magani.

 La'akari 
Ayyukan haɓaka rigakafin rigakafin cutar zazzabin cizon sauro wani tsari ne mai rikitarwa. Akwai la'akari da yawa da za a yi game da dabarun da yuwuwar rigakafin ya kamata a ɗauka.

 Bambancin parasite 
P. falciparum ya nuna iyawa, ta hanyar haɓaka ƙwayoyin cuta masu jure wa ƙwayoyi, don canjin juyin halitta. Nau'in <i id="mwAQs">Plasmodium</i> yana da babban adadin maimaitawa, fiye da yadda ake buƙata a zahiri don tabbatar da watsawa a cikin yanayin rayuwa.Wannan yana ba da damar jiyya na magunguna waɗanda ke da tasiri wajen rage yawan haifuwa, amma ba dakatar da <span title="This claim needs references to reliable sources. (April 2023)">shi</span> ] [ don yin babban zaɓi na zaɓi, don haka yana fifita ci gaban juriya. Tsarin canjin juyin halitta yana ɗaya daga cikin mahimman abubuwan da ake la'akari yayin la'akari da yuwuwar masu neman rigakafin. Haɓaka juriya na iya haifar da raguwar fa'ida ga kowane yuwuwar rigakafin don haka yin mara amfani da ingantaccen ingantaccen magani mai inganci. 

 Zaɓin magance alamar ko tushen 
Kwayoyin cuta suna haifar da manyan nau'ikan amsa guda biyu daga tsarin garkuwar jikin mutum. Waɗannan su ne rigakafin cutar parasitic da rigakafi mai guba.

 "Anti-parasitic rigakafi" yana magance tushen; ya ƙunshi amsawar antibody ( rigakafi mai ban dariya ) da amsawar rigakafi ta hanyar tantanin halitta. Da kyau, maganin alurar riga kafi zai ba da damar haɓaka ƙwayoyin rigakafi na anti-plasmodial ban da samar da amsa mai matsakaicin matsakaicin tantanin halitta. Za'a tattauna yuwuwar antigens waɗanda za'a iya yin niyya akan maganin rigakafi a cikin zurfin zurfi daga baya. Kwayoyin rigakafi wani ɓangare ne na takamaiman amsawar rigakafi. Suna aiwatar da tasirin su ta hanyar kunna cascade ɗin da suka dace, suna motsa ƙwayoyin phagocytic zuwa cikin endocytosis ta hanyar mannewa saman saman abubuwan antigenic na waje, don haka 'alama' shi a matsayin m. Kariyar barkwanci ko tantanin halitta ta ƙunshi hanyoyin haɗin kai da yawa waɗanda ke da nufin hana kamuwa da cuta shiga cikin jiki (ta hanyar shinge na waje ko maƙiyi na cikin gida) sannan kuma kashe duk wani ƙananan ƙwayoyin cuta ko ƙwayoyin waje waɗanda suka sami nasarar shiga. Ƙungiyar tantanin halitta ta ƙunshi yawancin fararen jini (irin su monocytes, neutrophils, macrophages, lymphocytes, basophils, mast cells, kwayoyin kisa na halitta, da eosinophils ) waɗanda ke kaiwa ga jikin waje ta hanyoyi daban-daban. Game da cutar zazzabin cizon sauro, za a yi niyya duka tsarin biyu don ƙoƙarin ƙara yuwuwar martanin da aka samar, don haka tabbatar da mafi girman damar hana cututtuka. 
 "Anti-mai guba rigakafi" yana magance alamun; yana nufin ƙaddamar da amsawar rigakafi da ke hade da samar da abubuwan da ko dai haifar da bayyanar cututtuka ko kuma rage tasirin da duk wani abu mai guba (na ƙananan ƙwayoyin cuta) yana da tasiri akan ci gaban cututtuka. Alal misali, an nuna cewa ƙwayar cuta necrosis factor-alpha yana da muhimmiyar rawa wajen haifar da alamun da aka samu a cikin mummunar cutar maleriya ta P. falciparum . Don haka maganin warkewa zai iya kaiwa ga samar da TNF-a, hana damuwa na numfashi da alamun kwakwalwa. Wannan hanya tana da ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun abubuwa kamar yadda ba zai rage nauyin parasitic ba; maimakon haka, kawai yana rage cututtukan cututtukan da ke haɗuwa. Sakamakon haka, akwai matsaloli masu yawa wajen kimanta inganci a cikin gwajin ɗan adam.

Yin la'akari da wannan bayanin, ingantaccen ɗan takarar rigakafin rigakafi zai yi ƙoƙarin samar da mafi mahimmancin amsawar tantanin halitta da kuma rigakafin ƙwayoyin cuta akan gabatarwar parasite. Wannan zai sami fa'ida ta haɓaka ƙimar kawar da ƙwayoyin cuta, don haka rage gogaggun alamun bayyanar cututtuka da kuma samar da daidaitaccen rigakafi na gaba a gaba.

 Maƙasudai masu yiwuwa 
+Maƙasudin rigakafin rigakafin cutar zazzabin cizon sauro (Dolan da Hoffman) Matakin parasite manufa Sporozoite Hepatocytes mamayewa; kai tsaye anti-sporozite Hepatozoite Kai tsaye anti-hepatozoite. Asexual erythrocytic Anti-host erythrocyte, antibodies toshe mamayewa; anti receptor ligand, anti-soluble guba Gametocyte Anti-gametocyte. Anti-host erythrocyte, ƙwayoyin rigakafi suna toshe hadi, ƙwayoyin rigakafi suna toshe fitowa daga sauro midgut.
Ta hanyar dabi'ar su, protozoa sun fi kwayoyin halitta da kwayoyin cuta da ƙwayoyin cuta, masu rikitarwa da tsarin rayuwa. Wannan yana gabatar da matsaloli a cikin ci gaban rigakafin amma kuma yana ƙara yawan abubuwan da za a iya kaiwa ga rigakafin. An taƙaita waɗannan a cikin matakin rayuwa da ƙwayoyin rigakafi waɗanda zasu iya haifar da amsawar rigakafi.[ <span title="This claim needs references to reliable sources. (April 2023)">abubuwan da ake bukata</span> ]

Kwayar cutar zazzabin cizon sauro ta bambanta sosai a duk faɗin duniya kuma ta haifar da imani cewa yana iya zama dole a ɗauki dabarun haɓaka rigakafi daban-daban don kaiwa ga al'ummomi daban-daban. Ana ba da shawarar allurar rigakafin nau'in 1 ga waɗanda galibi suna fama da cutar zazzabin P. falciparum a yankin Saharar Afirka, tare da manufar farko don rage yawan masu kamuwa da cutar zazzabin cizon sauro mai tsanani da kuma mace-mace a jarirai da yaran da suka kamu da cutar. Ana iya ɗaukar rigakafin nau'in 2 a matsayin rigakafin 'matafiya',' da nufin hana duk alamun asibiti a cikin mutanen da ba su da wani fallasa a baya. Wannan wata babbar matsala ce ta lafiyar jama'a, tare da bayyanar cutar zazzabin cizon sauro a matsayin daya daga cikin manyan barazana ga lafiyar matafiya. Matsaloli tare da samuwan hanyoyin kwantar da hankali sun haɗa da farashi, samuwa, sakamako mara kyau da rashin daidaituwa, rashin jin daɗi, da yarda, da yawa daga cikinsu za a rage ko kawar da su idan an samar da maganin rigakafi mai tasiri (fiye da 85-90%).[ <span title="This claim needs references to reliable sources. (November 2013)">abubuwan da ake bukata</span> ]

Halin rayuwa na kwayar cutar malaria yana da rikitarwa musamman, yana gabatar da matsalolin haɓaka na farko. Duk da ɗimbin yawan alluran rigakafin da ake da su, babu waɗanda ke da alaƙa da cututtukan parasitic. Matakan haɓaka daban-daban waɗanda ke cikin zagayowar rayuwa suna ba da dama da yawa don yin niyya ga antigens, don haka yana iya haifar da amsawar rigakafi. A bisa ka'ida, kowane mataki na ci gaba na iya samun maganin alurar riga kafi da aka samar da shi musamman don kai hari. Haka kuma, duk wani allurar rigakafin da aka samar zai kasance yana da ikon zama mai darajar warkewa tare da hana ci gaba da yaduwa kuma yana yiwuwa ya ƙunshi haɗin antigens daga matakai daban-daban na ci gaban parasites. Fiye da 30 daga cikin waɗannan antigens ana bincike  ta ƙungiyoyi a duk faɗin duniya a cikin bege na gano haɗin gwiwa wanda zai iya haifar da rigakafi a cikin mutumin da aka yi wa allurar. Wasu daga cikin hanyoyin sun haɗa da bayyanar da antigen, abubuwan hanawa na takamaiman ƙwayoyin rigakafi akan tsarin rayuwa da kuma tasirin kariya ta hanyar rigakafi ko canja wurin ƙwayoyin rigakafi tsakanin garkuwar jiki da mara lafiya. Galibin bincike kan allurar rigakafin zazzabin cizon sauro sun mayar da hankali ne kan nau’in Plasmodium falciparum saboda yawan mace-macen da kwayar cutar ke haifarwa da kuma saukin gudanar da binciken in vitro/in vivo. Maganin farko sun yi ƙoƙarin yin amfani da furotin circumsporozoite (CSP). Wannan shine mafi rinjayen antigen na farkon lokacin pre-erythrocytic. Duk da haka, an fuskanci matsalolin saboda ƙananan inganci, reactogenicity da ƙananan immunogenicity . 

 The initial stage in the lifecycle, following inoculation, is a relatively short "pre-erythrocytic" or "hepatic" phase. A vaccine at this stage must have the ability to protect against sporozoites invading and possibly inhibiting the development of parasites in the hepatocytes (through inducing cytotoxic T-lymphocytes that can destroy the infected liver cells). However, if any sporozoites evaded the immune system they would then have the potential to be symptomatic and cause the clinical disease.
 The second phase of the lifecycle is the "erythrocytic" or blood phase. A vaccine here could prevent merozoite multiplication or the invasion of red blood cells. This approach is complicated by the lack of MHC molecule expression on the surface of erythrocytes. Instead, malarial antigens are expressed, and it is this towards which the antibodies could potentially be directed. Another approach would be to attempt to block the process of erythrocyte adherence to blood vessel walls. It is thought that this process is accountable for much of the clinical syndrome associated with malarial infection; therefore, a vaccine given during this stage would be therapeutic and hence administered during clinical episodes to prevent further deterioration.
 The last phase of the lifecycle that has the potential to be targeted by a vaccine is the "sexual stage". This would not give any protective benefits to the individual inoculated but would prevent further transmission of the parasite by preventing the gametocytes from producing multiple sporozoites in the gut wall of the mosquito. It therefore would be used as part of a policy directed at eliminating the parasite from areas of low prevalence or to prevent the development and spread of vaccine-resistant parasites. This type of transmission-blocking vaccine is potentially very important. The evolution of resistance in the malaria parasite occurs very quickly, potentially making any vaccine redundant within a few generations. This approach to the prevention of spread is therefore essential.
 Another approach is to target the protein kinases, which are present during the entire lifecycle of the malaria parasite. Research is underway on this, yet production of an actual vaccine targeting these protein kinases may still take a long time.
 Report of a vaccine candidate capable of neutralizing all tested strains of Plasmodium falciparum, the most deadly form of the parasite causing malaria, was published in Nature Communications by a team of scientists from the University of Oxford in 2011.  The viral vector vaccine, targeting a full-length P. falciparum reticulocyte-binding protein homologue 5 (PfRH5) was found to induce an antibody response in an animal model.  The results of this new vaccine confirmed the utility of a key discovery reported from scientists at the Wellcome Trust Sanger Institute, published in Nature.   The earlier publication reported P. falciparum relies on a red blood cell surface receptor, known as 'basigin', to invade the cells by binding a protein PfRH5 to the receptor.  Unlike other antigens of the malaria parasite which are often genetically diverse, the PfRH5 antigen appears to have little genetic diversity.  It was found to induce very low antibody response in people naturally exposed to the parasite.   The high susceptibility of PfRH5 to the cross-strain neutralizing vaccine-induced antibody demonstrated a significant promise for preventing malaria in the long and often difficult road of vaccine development.  According to Professor Adrian Hill, a Wellcome Trust Senior Investigator at the University of Oxford, the next step would be the safety tests of this vaccine. At the time (2011) it was projected that if these proved successful, the clinical trials in patients could begin within two to three years.
 PfEMP1, one of the proteins known as variant surface antigens (VSAs) produced by Plasmodium falciparum, was found to be a key target of the immune system's response against the parasite.  Studies of blood samples from 296 mostly Kenyan children by researchers of Burnet Institute and their cooperators showed that antibodies against PfEMP1 provide protective immunity, while antibodies developed against other surface antigens do not.   Their results demonstrated that PfEMP1 could be a target to develop an effective vaccine which will reduce risk of developing malaria.
 Plasmodium vivax is the common malaria species found in India, Southeast Asia and South America.   It is able to stay dormant in the liver and reemerge years later to elicit new infections.  Two key proteins involved in the invasion of the red blood cells (RBC) by P. vivax are potential targets for drug or vaccine development.  When the Duffy binding protein (DBP) of P. vivax binds the Duffy antigen (DARC) on the surface of RBC, process for the parasite to enter the RBC is initiated.  Structures of the core region of DARC and the receptor binding pocket of DBP have been mapped by scientists at the Washington University in St. Louis.  The researchers found that the binding is a two-step process that involves two copies of the parasite protein acting together like a pair of tongs that "clamp" two copies of DARC.    Antibodies that interfere with the binding by either targeting the key region of the DARC or the DBP will prevent the infection.
 Antibodies against the Schizont Egress Antigen-1 (PfSEA-1) were found to disable the parasite's ability to rupture from the infected red blood cells (RBCs), thus preventing it from continuing with its lifecycle.  Researchers from Rhode Island Hospital identified Plasmodium falciparum PfSEA-1, a 244 kd malaria antigen expressed in the schizont-infected RBCs.  Mice vaccinated with the recombinant PfSEA-1 produced antibodies which interrupted the schizont rupture from the RBCs and decreased the parasite replication.  The vaccine protected the mice from the lethal challenge of the parasite.  Tanzanian and Kenyan children who have antibodies to PfSEA-1 were found to have fewer parasites in their bloodstream and a milder case of malaria.  By blocking the schizont outlet, the PfSEA-1 vaccine may work synergistically with vaccines targeting the other stages of the malaria lifecycle such as hepatocyte and RBC invasion.

Mix na antigenic aka gyara 
Ana iya samun haɓaka yuwuwar rigakafin da aka haifar akan Plasmodia ta yunƙurin ƙaddamar da matakai da yawa a cikin rayuwa. Wannan kuma yana da fa'ida wajen rage yuwuwar haɓakar ƙwayoyin cuta masu juriya. Yin amfani da antigens da yawa-parasites na iya samun sakamako na aiki tare ko ƙari.

Ɗaya daga cikin masu neman maganin alurar riga kafi a gwaji na asibiti ya ƙunshi sunadaran antigenic da suka sake haɗawa zuwa furotin na circumsporozoite . 

 Tarihi 
Mutanen da suka kamu da kwayar cutar a cikin ƙasashe masu fama da cutar suna samun rigakafi daga cututtuka da mutuwa. Irin wannan rigakafi baya hana kamuwa da cutar maleriya; Mutanen da ke da rigakafi sukan ɗauki kwayoyin cutar asymptomatic a cikin jininsu. Wannan yana nuna, duk da haka, yana nuna cewa yana yiwuwa a ƙirƙiri martanin rigakafi wanda ke ba da kariya daga cutarwar ƙwayar cuta.

Bincike ya nuna cewa idan aka dauki immunoglobulin daga manya masu rigakafi, an tsarkake su, sannan a ba wa mutanen da ba su da wani kariya, za a iya samun wasu kariya. 

 Ciwon sauro 
A cikin shekara ta 1967, an ba da rahoton cewa za a iya ba da matakin rigakafi ga ƙwayar ƙwayar cuta ta Plasmodium berghei ga beraye ta hanyar fallasa su ga sporozoites waɗanda aka lalata su ta hanyar x-ray.  Nazarin ɗan adam na baya a cikin 1970s ya nuna cewa za a iya yiwa ɗan adam rigakafi daga Plasmodium vivax da Plasmodium falciparum ta hanyar fallasa su ga cizon adadi mai yawa na sauro da ba su da iska. 

Daga shekara ta 1989 zuwa shekarar 1999, masu sa kai goma sha ɗaya da aka ɗauka daga Ma'aikatar Kiwon Lafiyar Jama'a ta Amurka, Sojojin Amurka, da Sojojin Ruwa na Amurka an yi musu rigakafi daga Plasmodium falciparum ta cizon sauro na 1001-2927 waɗanda aka lalata da rads 15,000 na gamma radiation daga Co. -60 ko Cs-137 tushen.  Wannan matakin radiation ya isa ya rage ƙwayar cutar zazzabin cizon sauro ta yadda, yayin da suke iya shiga cikin ƙwayoyin hanta, ba za su iya haɓaka zuwa schizonts ba kuma ba za su iya cutar da jajayen ƙwayoyin jini ba.  A cikin tsawon makonni 42, gwaje-gwaje 24 cikin 26 da aka yi wa masu aikin sa kai sun nuna cewa an kare su daga cutar zazzabin cizon sauro. 

 Kara karantawa 







 The Jordan Report










 Hanyoyin haɗi na waje 


 Malaria Vaccine Initiative 
 Malaria vaccines UK 
 Gates Foundation Global Health: Malaria

 Manazarta 
Rukuni:Rigakafi
Rukuni:Shafuka masu fassarorin da ba'a duba ba